Technique For Treatment Of Cancer Research Articles

Cancer Detection and Treatment Using Explainable AI

Cancer detection and treatment is one of the most difficult tasks in modern medicine, hence it has become a priority for researchers to study and develop specific and targeted procedures to patient outcomes. Just recently, the most promising direction is the humanization of explainable AI (XAI) which is a crucial tool for enhancing AI-based decision making in terms of transparency, and understandability. This paper starts out by describing conventional AI techniques for cancer detection and pointing out the informational gaps then delves into XAI's foundations. It explores the role of XAI in cancer detection and treatment by looking at its potential impact on this topic. It first presents the diagnosis of medical imaging data, then a discussion how patients' data will be interpreted by a XAI system and how treatment strategies that are tailored to the individual patient will be developed by optimizing the therapeutic interventions. This paper also presents comprehensive study of the changing side cancer treatment rendered by XAI and explain why further research and cooperation are getting to be of paramount importance in order for it to be fully exploited. Implementation of XAI in screening and treatment techniques for cancer comes to the conclusion of not only revolutionizing precision medicine, but also aiding in the improvement of patient care and will determine oncology practice in future.

All-in-One Nanohybrids Combining Sonodynamic Photodynamic and Photothermal Therapies.

A wide variety of methods are being developed to ultimately defeat cancer; while some of these strategies have shown highly positive results, there are serious obstacles to overcome to completely eradicate this disease. So, it is crucial to construct multifunctional nanostructures possessing intelligent capabilities that can be utilized to treat cancer. A possible strategy for producing these multifunctional nanostructures is to combine various cancer treatment techniques. Based on this point of view, we successfully synthesized multifunctional HCuS@Cu2S@Au-P(NIPAM-co-AAm)-PpIX nanohybrids. The peculiarities of these thermosensitive polymer-modified and protoporphyrin IX (PpIX)-loaded hollow nanohybrids are that they combine photodynamic therapy (PDT), sonodynamic therapy (SDT), and photothermal therapy (PTT) with an intelligent design. As an all-in-one nanohybrids, HCuS@Cu2S@Au-P(NIPAM-co-AAm)-PpIX nanohybrids were employed in the SDT-PDT-PTT combination therapy, which proved to have a synergistic therapeutic effect for in vitro tumor treatments against breast tumors.

Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in gastrointestinal cancers.

Gastrointestinal (GI) cancer is a prevalent disease and is recognized as the primary cause of cancer-related mortality globally. Therefore, there is an urgent need for novel diagnostic and treatment approaches for GC. The methylation of the O(6)-methylguanine DNA methyltransferase (MGMT) gene promoter is a significant factor in the development of colorectal cancer (CRC), namely in roughly 30-40% of cases where the cancer has spread. MGMT plays a role in the repair of DNA damage caused by methylating drugs like temozolomide (TMZ) and chloroethylating compounds like carmustine. As a result, it contributes to the resistance of chemotherapy when these agents are utilized. Although MGMT's role in the development of CRC is well established, its prognostic significance remains a subject of debate. Only a limited number of research have been conducted to examine the prognostic significance of MGMT methylation, yielding varying outcomes. This review explores the structural functions and repair processes of MGMT, focusing on the putative structural and functional significance of the N-terminal domain of MGMT. It also investigates the advancement of cancer treatment techniques that specifically target MGMT.

Microwave dielectric properties of normal, fibroelastotic, and malignant human lung tissue

Technological development of microwave treatment and detection techniques for lung cancer requires accurate and comprehensive knowledge of the microwave dielectric properties of human lung tissue. We characterize the dielectric properties of room temperature human lung tissue from 0.5 to 10 GHz for three lung tissue groups: normal, fibroelastotic, and malignant. We fit a two-pole Debye model to the measured frequency-dependent complex permittivity and calculate the median Debye parameters for the three groups. We find that malignant lung tissue is approximately 10% higher in relative permittivity and conductivity compared to normal lung tissue; this trend matches previously reported normal versus malignant data for other biological tissues. There is little contrast between benign lung tissue with fibroelastosis and malignant lung tissue. We extrapolate our data from room temperature to 37 °C using a temperature-dependence model for animal lung tissue and use the Maxwell-Garnett dielectric mixing model to predict the dielectric properties of inflation-dynamic human lung tissue; both approximations correspond with previously reported dielectric data of bovine and porcine lung tissue.

CT-Guided Percutaneous Cryoablation of Breast Cancer: A Single-Center Experience.

This study shall retrospectively evaluate the efficacy and safety of liquid-nitrogen based CT-guided cryoablation (CA) as a minimal-invasive technique for the curative treatment of primary breast cancer. A total of 45 female patients with 56 tumors were treated by CT-guided CA in analgosedation as an outpatient procedure. We used a liquid-nitrogen based system with a single cryoprobe and performed two freeze cycles with an intermediate thawing. The mean tumor diameter was 1.6 ± 0.7 cm. Follow-up was conducted via contrast-enhanced MR images of the breast. No complications were observed in all 56 ablations. Initial complete ablation was achieved in 100% of cases. Four cases of local tumor progression were reported, resulting in a rate of 8.9%, and 6 cases of intramammary distant recurrence at a rate of 13.3%. The extramammary tumor progression was observed in 7 patients at a rate of 15.6%. The mean overall survival was 4.13 years (95% CI: 3.7-4.5). The mean overall progression-free survival was 2.5 years (95% CI: 1.8-3.2) and the mean local progression-free survival was 2.9 years (95% CI: 2.3-3.6). Cryoablation is a safe and effective treatment for primary breast cancer tumors, which can be performed in analgosedation and as an outpatient procedure. However, potential for improvement exists and further evidence is necessary.

Magnetic‐Driven Hydrogel Spiral PVA/Fe3O4 Micromotors for Targeted Photothermal Therapy

AbstractPhototherapy has emerged as a promising technique for cancer treatment, offering high efficiency and minimal side effects. Nevertheless, conventional phototherapy agents suffer from low targetability and inefficient delivery. Here, a novel approach is proposed using helical hydrogel motors fabricated by combining polyvinyl alcohol, melamine, water, and Fe3O4 nanoparticles. These magnetic motors are capable of precise therapy on tumor cells driven by an external magnetic field. By converting light into heat upon near‐infrared illumination, the motors elevate the temperature of the targeted region, resulting in a significant therapeutic effect, with over 60% eradication of HeLa cells achieve under 808 nm near‐ infrared light (1.5 W cm−2). These helical micromotors exhibit excellent movement performance and biocompatibility, facilitating their in vivo applications and contributing to the advancement of biomedicine.

Trends in the surgical treatment for metastatic spinal tumor in Japanese administrative data between 2012 and 2020.

Both cancer diagnosis/treatment modality and surgical technique for the spine have been developed recently. Nationwide trends in the surgical treatment for metastatic spinal tumors have not been reported in the last decades. This study aimed to examine recent trends in the surgical treatment for spinal metastasis and in-hospital patient outcomes using nationwide administrative hospital discharge data. The Diagnosis Procedure Combination database from 2012 to 2020 was used to extract data from patients who underwent surgical procedures for spinal metastasis with the number of non-metastatic spinal surgery at the institutions that have performed metastatic spine surgeries at least one case in the same year. Trends in the surgical treatment for spinal metastasis, patients' demographics, and in-hospital mortality/outcomes were investigated. This study analyzed 10,321 eligible patients with spinal metastasis. The surgical treatment for spinal metastasis increased 1.68 times from 2012 to 2020, especially in fusion surgery, whereas the proportion of metastatic spinal surgery retained with a slight increase in the 2%s. Distributions of the primary site did not change, whereas age was getting older. In-hospital mortality and length of stay decreased over time (9.9-6.8%, p < 0.001; 37-30days, p < 0.001). Postoperative complication and unfavorable ambulatory retained stable and slightly decreased, respectively. During the last decade, surgical treatment for spinal metastasis, especially fusion surgery, has increased in Japan. In-hospital mortality and length of stay decreased. Recent advances in cancer treatment and surgical techniques might influence this trend.

Pilot robotic mastectomy in Singapore (PRoMiSing I) study: first safety and feasibility prospective cohort trial in South East Asia.

Robotic mastectomy has been performed worldwide since 2015. The advantages of the robotic approach in nipple-sparing mastectomy have been proven with better visualization and preservation of blood supply to the nipple-areolar complex, with a lower incidence of necrosis. It also allows smaller incisions for both mastectomy and immediate breast reconstruction. To date, no centers in Singapore and Southeast Asia offer robotic mastectomy. We believe that robotic mastectomy is a feasible and safe technique that our population can utilize. This study aimed to ascertain the surgical outcomes and perform a learning curve analysis in patients undergoing robotic mastectomy in a multi-ethnic South East Asian population. A single-arm prospective pilot study of eligible patients aged 21-70 years old with early breast cancer or high-risk patients indicated for risk-reducing mastectomy who were eligible and consented to robotic mastectomy were enrolled in this trial from December 22, 2022 to December 15, 2023. A total of 29 consecutive robotic mastectomies were performed. The mean total operative time was 95±10.2min. The average blood loss was 5.7±1.9ml, and the average length of stay was 1.05 days. The mean mastectomy specimen weight was 251g, and there was no conversion to conventional mastectomy in any case. Furthermore, there were no 30-day morbidity or complications in terms of wound infection requiring intervention, flap, and nipple-areolar complex necrosis, and postoperative hematoma/bleeding requiring intervention. This study contributes to the current evidence that robotic mastectomy is a safe and feasible option and could prove to be a great alternative to conventional mastectomy. Further prospective trials examining the long-term oncological outcomes of robotic mastectomy will be performed to establish the oncologic safety of this technique in breast cancer treatment.

A Hybrid Nanotube Stamp System in Intracellular Protein Delivery for Cancer Treatment and NMR Analytical Techniques.

In contrast to intracellular gene transfer, the direct delivery of expressed proteins is a significantly challenging yet essential technique for elucidating cellular functions, including protein complex structure, liquid-liquid phase separation, therapeutic applications, and reprogramming. In this study, we developed a hybrid nanotube (HyNT) stamp system that physically inserts the HyNTs into adhesive cells, enabling the injection of target molecules through HyNT ducts. This system demonstrates the capability to deliver multiple proteins, such as lactate oxidase (LOx) and ubiquitin (UQ), to approximately 1.8 × 107 adhesive cells with a delivery efficiency of 89.9% and a viability of 97.1%. The delivery of LOx enzyme into HeLa cancer cells induced cell death, while enzyme-delivered healthy cells remained viable. Furthermore, our stamp system can deliver an isotope-labeled UQ into adhesive cells for detection by nuclear magnetic resonance (NMR).

Teknik Terapi Radiasi 3DCRT Pada Kasus Kanker Serviks Dengan Studi Literatur

Research with literature studies is still rarely carried out, therefore in this article we want to know about the External Radiation Radiotherapy Technique in Cervical Cancer Cases with 3D-CRT (3-Dimensional Conformal Radiation Therapy): This literature discusses the application of the 3D-CRT external radiation radiotherapy technique in treatment cervical cancer. 3D-CRT is a method that allows external radiation exposure from more than one side,possiblemore appropriate radiation dose according to the shape and location of the tumor. This study also lists other techniques such as Brachytherapy, IMRT, and 2D in the treatment of cervical cancer. Photon Dose Distribution Using 3D-CRT and IMRT Techniques in Cervical Cancer Therapy: This research discusses photon dose distribution in the Treatment Planning System (TPS) using 3DCRT and IMRT techniques for cervical cancer therapy. This provides insight into the comparison between the two techniques in delivering appropriate radiation doses to the tumor target. 6 MV Energy Linac Radiotherapy Against Cervical Cancer: This journal discusses the use of radiotherapy on a Linac aircraft with a 6 MV energy photon beam using the 3DCRT technique in the treatment of cervical cancer. This technique helps deliver the right dose of radiation according to the target area. The literature above provides information about external radiotherapy techniques, including 3D-CRT, in the treatment of cervical cancer. They help understand the role and application of this technique in cervical cancer treatment.

Cutting-Edge Innovations in Minimally Invasive Techniques for Skin Cancer Treatment

Skin cancer is a common and possibly deadly disease that requires immediate and efficient treatment. Conventional surgical methods, although successful, frequently lead to the formation of scars and extended periods of recuperation. In recent years, there have been significant developments in minimally invasive treatments for treating skin cancer. These techniques provide patients with alternative options that result in better cosmetic outcomes and shorter recovery periods. This article is a comprehensive summary of state-of-the-art advancements in minimally invasive procedures, including as laser therapy, cryotherapy, electrochemotherapy, and radiofrequency ablation. We analyze the benefits of these procedures, including minimized scarring, improved cosmetic outcomes, and faster healing periods, while also examining the difficulties and factors involved in their application. We showcase the concrete advantages that patients receive when they undergo minimally invasive therapy for skin cancer, using case studies and success stories as evidence. In addition, we examine potential future paths in research and development, anticipating a favorable outlook for the ongoing use of minimally invasive methods in the treatment of skin cancer. The global prevalence of skin cancer is a substantial health issue, leading to continuous progress in treatment strategies aimed at enhancing patient results. Conventional surgical techniques, however efficient, can lead to conspicuous scarring and extended recuperation periods. Recent advancements in minimally invasive procedures have significantly transformed the treatment of skin cancer, providing patients with alternative options that yield better esthetic results and shorter recovery periods. This article offers a comprehensive analysis of state-of-the-art advancements in minimally invasive procedures, encompassing laser therapy, cryotherapy, electrochemotherapy, and radiofrequency ablation. We use case studies and success stories to demonstrate the concrete advantages that patients gain from these operations, such as minimized scarring and improved cosmetic outcomes. In addition, we explore the difficulties and factors to take into account when putting these methods into practice, along with potential areas for further investigation and advancement. Our goal is to emphasize the hopeful future of minimally invasive treatments in skin cancer care, which will ultimately enhance patient experiences and outcomes.

Facile manganese ion-coordination assembly of nanogels for synergistic cancer chemo–chemodynamic-immunotherapy

Metal-ion therapy is an emerging technique for cancer treatment, where anticancer metals trigger an immune response against tumor cells due to immunogenic cell death while enabling chemokinetic therapy, and the integration of these activities holds considerable anticancer potential for achieving high specificity and efficiency. Herein, we designed acid-responsive manganese-based nanogels with high drug-loading capacity for combined chemotherapy, chemodynamic therapy, and metal-immune therapy. The chemotherapeutic drug mitoxantrone, metallic manganese ions, and polymeric polyacrylic acid self-assembled into stable nanogels that could be efficiently internalized by cancer cells efficiently, releasing Mn2+ to catalyze highly toxic of hydroxyl generation from endogenous H2O2 and induce tumor cell apoptosis. Furthermore, the Mn2+-mediated activation of cyclic guanosine monophosphate adenosine synthetase activated the stimulator of interferon genes (STING) pathway, thereby inducing dendritic cell maturation. Following intravenous injection into immunocompetent tumor-bearing mice, the nanogels effectively exerted a tumor-killing effect and enhanced the antitumor immune response in combination with an aCTLA-4 antibody. Manganese ions also enhanced T1-weighted magnetic resonance imaging for integrated diagnosis and treatment. Overall, the manganese-based nanogel demonstrates significant synergistic efficacy through combined chemotherapy, chemodynamic therapy and metal-immune therapy, providing a versatile therapeutic strategy for cancer treatment.

Pharmacological Targeting of Ferroptosis in Cancer Treatment

A non-apoptotic iron-dependent form of Regulated Cell Death (RCD) known as ferroptosis is brought on by an excess of harmful lipid peroxides and iron overload. Inhibiting the antioxidant defense system results in overwhelming of GSH dependent pathway and building up iron-dependent Reactive Oxygen Species (ROS) that react with polyunsaturated fatty acids in large quantities can both cause ferroptosis. Recent research has shown that ferroptosis holds a great deal of promise for preventing tumor cell resistance and limiting growth and spread. Emerging evidence also suggests that ferroptosis plays a dual role in human cancer. However, the precise underlying molecular mechanisms and their different role in tumorigenesis are unclear. Therefore, in this review we summarize and briefly present the key pathways of ferroptosis, its dual role as an oncogenic and as a tumor suppressor event in human cancers, paying special attention to the regulation of ferroptosis along with a variety of current medications and naturally occurring substances that may one day be used to target ferroptosis in tumor cells. Thus, addressing this sort of cell death could be seen as a potentially expanding technique in cancer treatment. Consequently, this will offer crucial viewpoints for next research on ferroptosis-based cancer treatment.&#x0D; Keywords: Ferroptosis, antioxidant defense system, Cancer

Evaluation of chlorophyll-loaded mesoporous silica nanoparticles for photodynamic therapy on cancer cell lines

Chlorophyll (Chl) is a promising natural photosensitizer (PS) in photodynamic treatment (PDT). Mesoporous silica nanoparticles (MSNs) were chosen to increase the effectiveness of PDT. This study aimed to evaluate the synergistic efficacy of chlorophyll-loaded mesoporous silica nanoparticles (Chl-MSNs) with photodynamic therapy (PDT) and to investigate their potential toxicity in HepG2, MDA-MB-231, and HSF cell lines. Chl-MSNs were prepared via the physical adsorption method. TEM, DLS, and zeta potential examined morphology, size, and surface characteristics. MSNs and Chl-MSNs were characterized using the same techniques. HPLC was used to assess the encapsulation efficiency. At pH 7.4, an in vitro release experiment of Chl-MSNs was performed. Chl, MSNs, and Chl-MSNs were applied to the three cell lines at different concentrations and subjected to red (650 nm) and blue (450–500 nm) lasers. MSNs and Chl-MSNs’ sizes were 90.338 ± 38.49 nm and 123.84 ± 15.67 nm, respectively, as obtained by TEM; the hydrodynamic diameter for MSNs (93.69 ± 20.53 nm) and Chl-MSNs (212.95 ± 19.76 nm); and their zeta potential values are − 16.7 ± 2.19 mV and − 18.84 ± 1.40 mV. The encapsulation efficiency of Chl-MSNs was 70%. Chl-MSNs displayed no toxicity in dark conditions but showed excellent photostability under blue and red light exposure. Furthermore, using Chl over Chl-MSNs has a higher PDT efficiency than the tested cell lines. Chl-MSNs have the potential to be an effective delivery system. PDT proved to be an essential technique for cancer treatment. Blue laser is recommended over red laser with Chl and MSNs for destroying cancer cells.Graphical

Micro and Nano Robotics-assisted Targeted Drug Delivery, Surgery and Radiotherapy for Cancer Treatment

Abstract: Cancer refers to the progressive abnormal cell growth with the potential to invade or spread to other parts of the body. Many cancer therapies continue to be based on systemic chemotherapy along with radiation therapy. Numerous nanomedicine strategies have been developed to address the untargeted nature of these therapies and the serious side effects they can cause. As targeted therapeutic delivery is still difficult, engineered robots and microrobots are getting more and more attention and applicability. Microrobots can more effectively reach malignancies because of their unique features and functions, like their motility, which allows them to penetrate malignant tissues. Modern cancer treatment techniques built on information technology can boost patient compliance and improve patient survival. The delicate tissue can be overly damaged by radiation and surgery, and most chemotherapy medications are unable to penetrate the blood-brain barrier and reach the tumor. Cancer prevention, its early detection, quick diagnosis, and prompt treatment are very crucial. Robotic technology is employed in a variety of medical settings, and its applications in surgery have evolved that have an impact on the field of cancer treatment as well. A key improvement in cancer therapy with the aid of robotics would be the ability to target and deliver medications directly to the tumor.

Cancer Pharmacology Advances: Fundamentals, Combination, Imagery, Shipment and Therapeutic Applications

Cancer continues to be a major health issue worldwide, necessitating creative solutions to medication production and therapy techniques. It delves into the concepts of cancer drug activity, mixtures of drugs, imaging of molecules, delivery of medications, the interaction between medications, clinical utility and use, and the place of cancer medications across the procedure for discovering and developing drugs. Cancer therapy assumptions serve as the cornerstone for treatment methods. This understanding contributes directly to the intelligent planning of focused medicines, which aim to deliberately interrupt these channels while minimizing outside-target consequences and adverse reactions. Genome and transcriptomic studies have supplied a lot of understanding to aid in inventing personalized treatment techniques in cancer treatment. Cancer pharmaco has been transformed by molecular imaging tools that provide immediate visualization of medication action in the tumour ecosystem. Investigators can monitor medication transportation, pharmaceutical kinetics, and therapeutic using PET and MRI, as well as other approaches, supporting personalized regimens for therapy. Cancer medication means of distribution have emerged in order to increase drug absorption, decrease poisoning, or enhance directed drug administration. Creative ideas for drug delivery techniques that have shown interest in clinical studies include micron-sized particles of liposomes and antibody-drug conjugates. In cancer survivors, extensive toxicological research and computer modelling are critical in discovering likely interactions and guiding choosing therapy and administration. Cancer pharmacology's clinical significance and applications span from test to bed.

Delivery of High-Intensity Proton Beam for the Study of Flash-Effect in Radiotherapy

Flash-therapy is a rapidly developing field of radiology that has the potential to revolutionize future cancer treatment techniques. The method involves delivery the therapeutic radiation dose to the tumor volume at an ultra-high dose rate in the beam, several orders of magnitude higher than that usually used in conventional radiotherapy. In this mode of irradiation, the degree of damage to normal tissues surrounding the tumor and falling under the influence of radiation decreases, at the same time, the effect on cancer cells remains at the same level, which preserves the prospect of local control of the tumor with a lower frequency of side effects.&#x0D; The paper presents the results on the delivery of a high-intensity proton beam with an energy of 660 MeV from the Phasotron of the Joint Institute for Nuclear Research, Dubna, designed for radiobiological studies under flash therapy irradiation of cell cultures and small laboratory animals (mice, rats). In addition, the main design features and parameters of the created detectors for measuring the characteristics of this beam are presented.

An adaptive conjugate gradient accelerated evolutionary algorithm for multi-objective spot optimization in cancer intensity modulated proton therapy

Intensity-modulate proton therapy is one of the most advanced cancer treatment techniques due to the Bragg peak characteristics of proton radiation. The personalized demand of different patients requires treatment optimization methods to quickly provide diverse treatment plans to select the best plan for a patient. However, most existing treatment optimization methods are transformed the multi-objective optimization problem into a single optimization problem. Moreover, the radiation physicists may adjust the objective weights repeatedly to produce a set of high-quality treatment plans. To address this problem, this paper proposes an adaptive conjugate gradient accelerated evolutionary algorithm (ACG-EA) to generate a set of diverse high-quality treatment plans simultaneously. The conjugate gradient method is employed as a directional mutation operator to accelerate the search process in the hybrid mutation operation. In addition, the weight parameters of the conjugate gradient are automatically updated based on the diversity and convergence of the current population. Compared with five representative multi-objective evolutionary algorithms, the experimental results have shown the competitive performance of the proposed ACG-EA on the hypervolume and dose-volume histogram indicators in six clinical cancer cases.

Design of a novel nanoparticle to use X-ray fluorescence of TiO2 to induce photodynamic effects in the presence of PpIX

BackgroundRadiotherapy and photodynamic therapy are the methods of cancer treatment. Although one limitation of photodynamic therapy (PDT) is the limited penetration depth of light through tissue, using X-rays does not have this restriction. Self-lighting nanoparticles can convert X-rays into UV/visible. This study focuses on a newly designed nanostructure containing mesoporous silica nanoparticles (MSN), titanium dioxide nanoparticles (TiO2, anatase grade), and protoporphyrin IX (PpIX) as a photosensitizer to overcome the limitations of photodynamic therapy. MethodsAfter the synthesis and characterization of Ti-MSN/PpIX@PVP nanostructure, two ROSes (OH* and 1O2) were measured when the nanostructures were irradiated with 100 kV and 6 MV photons. The toxicity of Ti-MSN/PpIX@PVP nanostructure in presence and absence of radiation was investigated on DFW and HT-29 cell lines. The in-vitro experiments were analyzed using the MTT assay and colony count assay. Finally, the effect of light exposure in the presence of Ti-MSN/PpIX@PVP nanostructure on the two cell lines was studied. The in-vitro studies were evaluated using the Synergism Index (Syn) and Dose Enhancement Factor (DEF). ResultsBased on the FESEM (field emission scanning electron Microscopy) images and DLS (dynamic light scattering) measurements, the size of Ti-MSN/PpIX nanostructure was determined as (35.2 nm) and (168.4 nm), respectively. Based on the spectrofluorimetry results, 100 kV photons produced more ROSes than 6 MV photons. The results of MTT assay and colony formation for X-PDT show Syn >1, except for 100 kV photons for HT-29 cell line. The nanostructure also reduced colony formation induced by X-PDT more effectively when irradiated by 100 kV photons on DFW cells. The results obtained from conventional PDT showed that the ED 50 of the HT-29 cell line was 6 times higher than that of the DFW cell line. ConclusionDesigning and synthesizing Ti-MSN/PpIX@PVP nanostructures offer a promising strategy for reducing the current challenges in PDT and for developing and advancing X-PDT as an innovative cancer treatment technique.

The design and virtual screening of thiourea derivatives as a Sirtuin-1 inhibitor

The SIRT1 is overexpressed in a number of cancers. As a result, inhibiting SIRT1 may be used as a cancer treatment technique. Modification of 1-benzoyl-3-methylthiourea derivatives was carried out in this study by changing the aromatic side. The designed compounds (94) were subjected to in silico docking, pharmacokinetics, and preclinical testing. In the docking sample, the (4-decyl-N-(methylcarbamothioyl)benzamide (91), 2-(benzyloxy)-N-(methylcarbamo-thioyl)benzamide (93) and N-(methylcarbamothioyl)-2-naphthamide (94) were predicted to display better inhibition of SIRT1, so they were chosen for subsequent molecular dynamic studies. The compound 93 is proposed as a possible anticancer candidate that inhibits SIRT1 based on the screening results from molecular docking, pharmacokinetic predictions, and molecular dynamics.